Get startedLog in
    Picture of Bavarian Nordic A/S logo

    BAVA — Bavarian Nordic A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapNeutral
    All News

    Brief: Bavarian Nordic Announces Sale Of Priority Review Voucher For $160 Mln

    Picture of Bavarian Nordic A/S logoBavarian Nordic A/S
    18/06/2025 08:12
    June 18 (Reuters) - Bavarian Nordic A/S BAVA.CO:

ANNOUNCES SALE OF PRIORITY REVIEW VOUCHER FOR USD 160 MILLION

PURSUANT TO A LICENSE AGREEMENT ASSUMED UPON ACQUISITION OF CHIKUNGUNYA VACCINE IN 2023, NATIONAL INSTITUTES OF HEALTH (NIH) WILL RECEIVE 20% OF GROSS PROCEEDS FROM SALE OF PRV

EBITDA WILL BE POSITIVELY IMPACTED, ANY IMPACT ON GUIDED EBITDA MARGIN OF 26-30% FOR 2025 TO BE UPDATED UPON CLOSING OF TRANSACTION

TRANSACTION REMAINS SUBJECT TO CUSTOMARY CLOSING CONDITIONS, INCLUDING ANTI-TRUST REVIEW, WHICH IS EXPECTED TO OCCUR IN Q3 OF 2025

Source text: ID:nGNE7VkKkd

Further company coverage: BAVA.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;))

    Recent news on Bavarian Nordic A/S

    See all news